• Hypogonadism

Vogelxo Generic Name & Formulations

General Description

Testosterone 50mg (in 5g gel); per tube or packet; 12.5mg (in 1.25g gel) per actuation; metered-dose pump.

Pharmacological Class


How Supplied

Tubes, pkts (5g)—1, 30; Pump 75g (60 metered 1.25g doses)—2

Vogelxo Indications


Testosterone replacement therapy.

Limitations of Use

Not established in men with age-related hypogonadism.

Vogelxo Dosage and Administration


Prior to treatment, confirm diagnosis by ensuring serum testosterone is below normal range as measured in the AM on at least 2 separate days. Advise patients to strictly adhere to recommended instructions. Apply to clean, dry intact skin of the shoulders and/or upper arms at the same time each day; do not apply to the genitals or abdomen. ≥18yrs: initially 50mg (1 tube or packet, or 4 pump actuations) once daily; measure morning, pre-dose serum testosterone levels approx. 14 days after initiation to ensure response. May increase to 100mg (2 tubes or packets, or 8 pump actuations) once daily based on serum testosterone concentration; max 100mg once daily. Wash hands after application. Allow gel to dry completely before dressing.


<18yrs: not established.

Vogelxo Contraindications


Male breast or prostate carcinoma. Pregnancy. Nursing mothers.

Vogelxo Boxed Warnings

Boxed Warning

Secondary exposure to testosterone.

Vogelxo Warnings/Precautions


Not for use in women. Not interchangeable with other topical testosterone products. Other persons (esp. children) must avoid contact with application site. Secondary exposure to testosterone; promptly discontinue if signs of virilization in children and women occurs, until cause is identified. Monitor for worsening BPH. Evaluate for prostate cancer prior to and during therapy. Monitor hematocrit prior to initiation, 3–6 months after starting therapy, then annually; if elevation occurs, withhold until acceptable level. Preexisting cardiac, renal or hepatic disease (discontinue if edema occurs). Obesity. Chronic lung diseases. Testosterone and/or other anabolic androgenic steroid abuse. Periodically monitor serum testosterone, PSA, liver function, and lipid profile. Monitor serum calcium if risk of hypercalcemia. Monitor for venous thromboembolism; discontinue if suspected. Inform patients of possible increased risk of MI, stroke. Flammable. Elderly.

Vogelxo Pharmacokinetics

See Literature

Vogelxo Interactions


May affect insulin sensitivity or glycemic control; reduce dose of antidiabetics. Monitor INR and PT with concomitant oral anticoagulants. Concomitant corticosteroids may increase fluid retention. May decrease thyroxine-binding globulins.

Vogelxo Adverse Reactions

Adverse Reactions

Application site reactions, increased hematocrit, increased blood pressure, headache; sleep apnea, polycythemia, azoospermia (w. large doses), venous thromboembolism (evaluate and discontinue if suspected), edema, gynecomastia, virilization in children.

Vogelxo Clinical Trials

See Literature

Vogelxo Note

Not Applicable

Vogelxo Patient Counseling

See Literature